$MSOS 100 Reasons to Be Bullish on $MSOS
Federal Legalization & Policy Tailwinds
Cannabis remains federally illegal — meaning the biggest upside is still ahead.
Rescheduling to Schedule III is underway.
Schedule III would eliminate 280E tax penalties.
SAFE Banking has bipartisan support.
SAFE Banking would unlock institutional capital.
Federal reform is now a mainstream political issue.
Public support for legalization is at all-time highs.
24+ states have adult-use markets.
38+ states have medical markets.
Federal agencies are softening enforcement stances.
Tax & Financial Catalysts
Removal of 280E would instantly boost MSO profitability.
MSOs could deduct normal business expenses.
Cash flow would surge across the industry.
Debt refinancing becomes easier post-reform.
Lower cost of capital improves margins.
U.S. exchanges could eventually uplist MSOs.
Uplisting would unlock billions in institutional inflows.
Index funds would be forced to buy MSOs.
Analyst coverage would expand dramatically.
Liquidity would improve across the sector.
Industry Growth
U.S. cannabis is the fastest-growing consumer industry in America.
The U.S. market is larger than Canada, Europe, and LatAm combined.
U.S. cannabis sales projected to exceed $50B by 2030.
Cannabis is replacing alcohol among younger demographics.
Medical cannabis demand continues to rise.
Cannabis is recession-resistant.
Cannabis tourism is expanding.
New states legalize every election cycle.
Legacy markets are stabilizing.
New product categories are emerging.
MSOS ETF Structure
MSOS is the only U.S.-focused actively managed cannabis ETF.
It holds the largest U.S. MSOs directly.
It provides diversified exposure across operators.
It reduces single-company risk.
It captures upside from multiple state markets.
It adjusts holdings dynamically.
It benefits from sector-wide catalysts.
It avoids Canadian LP overexposure.
It tracks the true U.S. cannabis economy.
It is the most liquid U.S. cannabis ETF.
Top Holdings Strength
Curaleaf is expanding globally.
Green Thumb Industries is consistently profitable.
Trulieve dominates Florida’s medical market.
Cresco Labs has strong wholesale distribution.
Verano has premium brand strength.
TerrAscend is expanding into high-value states.
Jushi is improving margins.
Ascend Wellness is growing in limited-license markets.
Planet 13 is a retail experience leader.
Ayr Wellness is restructuring for profitability.
State-Level Catalysts
Florida could legalize adult-use.
Pennsylvania is moving toward legalization.
Ohio is launching adult-use sales.
New York is fixing its rollout.
New Jersey is booming.
Maryland adult-use sales are surging.
Minnesota is building a new market.
Virginia could legalize sales.
Texas medical expansion is inevitable.
California is reforming taxes and enforcement.
Consumer Trends
Cannabis stigma is collapsing.
Cannabis is replacing prescription sleep aids.
Cannabis is replacing pain medications.
Edibles are growing rapidly.
Vapes remain a top category.
Pre-rolls are the fastest-growing segment.
Cannabis beverages are gaining traction.
Wellness-focused products are expanding.
Senior usage is rising.
Cannabis is becoming a mainstream lifestyle product.
Business Fundamentals
MSOs are cutting costs aggressively.
Many MSOs are already EBITDA-positive.
Cash flow improves as new states open.
Vertical integration boosts margins.
Wholesale markets are stabilizing.
Retail footprints are expanding.
Brand loyalty is increasing.
Operators are exiting unprofitable markets.
Debt loads are being refinanced.
Consolidation is accelerating.
Valuation Upside
MSOs trade at deep discounts to alcohol and tobacco.
Price-to-sales ratios are historically low.
Price-to-cash-flow ratios are extremely attractive.
Market caps don’t reflect future legalization.
Institutional capital is still on the sidelines.
Retail investors have not returned yet.
Short interest remains elevated.
Any federal catalyst could trigger a sector-wide re-rating.
MSOS offers asymmetric upside.
The sector is deeply oversold relative to fundamentals.
Long-Term Structural Advantages
Cannabis demand is permanent and growing.
The U.S. market is too large to remain federally restricted forever.
MSOs will dominate once federal barriers fall.
MSOS captures the entire industry’s growth curve.
Cannabis is becoming a normalized consumer packaged good.
The industry will eventually consolidate into national giants.
MSOS gives exposure to future national brands.
Cannabis will eventually be treated like alcohol.
The U.S. cannabis market will dwarf Canada’s.
MSOS is positioned to benefit from every major catalyst in the industry.
Bullish
Nothing I post is financial advice. I may hold long, short, or no positions in mentioned securities. I’ve never been paid to post. All content is for entertainment purposes only.
AI
